Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
J-J. Yang
Observed name:
JJ Yang
Institutions:
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University
Observed institutions:
Guangdong General Hospital,
IVL Swedish Environmental Research Institute,
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Allen Institute for Artificial Intelligence,
Southern Medical University
show all 6
OpenAlex ID:
A5106037814
Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study
2022
·
O Kouli
, V Murray
, et al.
·
The Lancet Digital Health
·
56
PDF
COVID-19 Open Research Dataset (CORD-19)
2020
·
Kohlmeier, Sebastian
, Lo, Kyle
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
39
PDF
Full-scale comparison of N2O emissions from SBR N/DN operation versus one-stage deammonification MBBR treating reject water – and optimization with pH set-point
2019
·
L. Kanders
, J-J. Yang
, et al.
·
Water Science & Technology
·
18
1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
2023
·
J-J. Yang
, Y. Zhang
, et al.
·
Annals of Oncology
·
13
PDF
629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naïve advanced ALK+ non-small cell lung cancer (NSCLC)
2024
·
C. Zhou
, Y. Lu
, et al.
·
Annals of Oncology
·
7
PDF
1272P Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
2024
·
J-J. Yang
, N. Pavlakis
, et al.
·
Annals of Oncology
·
6
PDF
20P Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)
2023
·
S-Y.M. Liu
, Q. Zhou
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
1953P PLB-1004 in advanced non-small cell lung cancer (NSCLC) with exon 20 insertion mutations (ex20ins): A multicenter, single-arm, phase II study
2025
·
J-J. Yang
, Y-L. Wu
, et al.
·
Annals of Oncology
·
2
420P Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
2023
·
X. Zhang
, Y. Chen
, et al.
·
Annals of Oncology
·
2
PDF
32O First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with advanced non-small cell lung cancer (NSCLC)
2021
·
H-J. Chen
, J-J. Yang
, et al.
·
Annals of Oncology
·
2
PDF
P3.12.26 Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC
2025
·
Z-J. Mao
, X-H. Guan
, et al.
·
Journal of Thoracic Oncology
·
1
19P: Subgroup analysis of first-line camrelizumab plus chemotherapy in brain metastases of NSCLC: Results from the CTONG 2003 trial
2025
·
Y-S. Li
, J-J. Yang
, et al.
·
Journal of Thoracic Oncology
·
1
61P: Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PDL1 expression
2025
·
C. Weng
, Y. Jiao
, et al.
·
Journal of Thoracic Oncology
·
1
1382P Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations
2024
·
M. Pérol
, M. Awad
, et al.
·
Annals of Oncology
·
1
PDF
75P PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)
2024
·
S-Y.M. Liu
, Q. Zhou
, et al.
·
ESMO Open
·
1
1364P ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
2023
·
J-J. Yang
, J. Zhou
, et al.
·
Annals of Oncology
·
1
PDF
50P Droplet digital PCR measurement of c-Met gene amplification in plasma cell free DNA in patients with advanced NSCLC
2016
·
H-F. Gao
, X. Zhang
, et al.
·
Annals of Oncology
·
1
439O Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs
2016
·
Y-C. Zhang
, C. Pi
, et al.
·
Annals of Oncology
·
1
P1.11.05 Efficacy and Multi-Omics Insights of Immune Checkpoint Inhibitors in NSCLC With Leptomeningeal Metastasis
2025
·
L-B.B. Tang
, Y-S. Li
, et al.
·
Journal of Thoracic Oncology
666P First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial
2024
·
J-J. Yang
, Y. Li
, et al.
·
Annals of Oncology
PDF
74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study
2024
·
J-J. Yang
, C. Huang
, et al.
·
ESMO Open
569P Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
2023
·
C-Y. Zhang
, H. Sun
, et al.
·
Annals of Oncology
PDF
566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
2023
·
C.K. Liam
, T.M. Kim
, et al.
·
Annals of Oncology
PDF
385P Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
2022
·
S-Y.M. Liu
, H-Y. Tu
, et al.
·
Annals of Oncology
454P Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression
2016
·
R-L. Chen
, N-N. Lou
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
30
Citation count:
156
H-index:
6
I10-index:
4
Year
Topic
Type